COVID-19 Vaccine human clinical trials: Immune response evaluation in various populations Umbrella Project (IIV-CIb/RIVM)



Immune responses are compared:

Specific risk groups studies by consortia (academia):

- Autoimmune disease and/or immune deficiency: Target2Be
- Primary immune deficiencies: VACOPID
- Cancer: VOICE
- Kidney disease and/or transplantation: RECOVAC
- Down syndrome: PRIDE
- Lung disease and/or transplantation: COVALENT

Evaluation of immune responses to SARS-CoV-2 infection in Dutch households

After 3 days, 2-3 weeks, 6 weeks and 10 months

FFX/RIVM

Harmonized timepoints

1. Before vaccination
2. 4 Weeks after 1st vaccination
3. 4 Weeks after 2nd vaccination
4. 6 Months after 2nd vaccination
5. 12 Months after 2nd vaccination

Harmonized measuring of antibodies

- High throughput bead-based multiplex immune assay (MIA)
- Antibody (IgG) 28 days after 2nd vaccination as primary parameter

Integrated approach

Majority of studies include a spectrum of immune responses:

- T-cells
- B-cells
- Innate cells
- Serology
- Local immunity (e.g. antibodies in the nose)
- Role of gut microbiome